For example, the TG2 inhibitor, GK921, has been shown to be effective in a xenograft model in renal cell cancer (RCC), the GK921-binding site overlaps with that of p53 and thus prevents it from binding to TG2, and therefore maintains the stability of the tumour suppressor activity of p53, resulting in a significant anticancer effect. This evidence concerns the gene TGM2 and renal cell carcinoma.